Migraine: Types, Root Causes, Regenerative Treatments, and What Actually Helps
At a Glance
- What it is: A neurological condition causing recurrent episodes of severe head pain, often with nausea, light sensitivity, and visual disturbances. Far more than “just a headache.”
- Who it affects: Roughly 1 billion people worldwide. Three times more common in women. Peak prevalence between ages 25 and 55.
- Conventional approach: Triptans, NSAIDs, CGRP inhibitors (Aimovig, Nurtec), beta-blockers, antidepressants. Effective for many, but 30-40% of patients do not respond adequately.
- Regenerative options: Ketamine infusions, neurofeedback, TMS, NAD+ IV, peptide therapy, vagus nerve stimulation, dietary interventions.
- Key insight: Migraine is increasingly understood as a disorder of brain excitability and neuroinflammation, not simply a pain condition. This reframing opens doors to regenerative and neuromodulatory treatments.
If you have ever told someone you have a migraine and heard “so, a bad headache?”, you already know the frustration. Migraine is not a headache. It is a complex neurological event that hijacks your brain’s electrical and chemical signaling, producing pain that can be debilitating, along with nausea, light and sound sensitivity, visual disturbances, cognitive impairment, and sometimes neurological symptoms that mimic stroke.
And for roughly a third of the people who get them, standard medications do not work well enough. This is where the conversation gets interesting: a growing body of research is exploring how neuromodulation, IV therapy, and regenerative approaches can address the underlying neurobiology of migraine rather than simply chasing the pain.
What Actually Happens During a Migraine
The current understanding of migraine has evolved significantly from the old “blood vessel constriction” theory. Migraine is now recognized as a disorder of the trigeminovascular system, a complex network connecting the trigeminal nerve, brain blood vessels, and brainstem pain-processing centers.
Here is the cascade, simplified:
- Cortical spreading depression (CSD): A wave of abnormal electrical activity spreads across the brain cortex. This is what causes aura (visual disturbances, tingling, language disruption) in the ~25% of patients who experience it.
- Trigeminal nerve activation: The spreading depression triggers the trigeminal nerve, which releases CGRP (calcitonin gene-related peptide) and other inflammatory neuropeptides.
- Neurogenic inflammation: CGRP dilates blood vessels around the brain and promotes inflammation of the meninges (brain coverings). This is the throbbing pain.
- Central sensitization: Repeated activation sensitizes brainstem pain centers, lowering the threshold for future attacks. This is why chronic migraine gets progressively worse without proper management.
Why this matters for treatment
Understanding migraine as a neuroinflammatory and excitability disorder (not just a pain problem) is what opens the door to treatments like ketamine, neurofeedback, and TMS. These approaches target the underlying neurological dysfunction rather than simply blocking pain signals downstream.
Types of Migraine
| Type | Key Features | Frequency |
|---|---|---|
| Migraine without aura | Moderate-to-severe unilateral throbbing pain, nausea, light/sound sensitivity. Lasts 4-72 hours. | Most common (~75% of migraineurs) |
| Migraine with aura | Visual, sensory, or language disturbances preceding headache. Aura lasts 20-60 minutes. | ~25% of migraineurs |
| Chronic migraine | 15+ headache days per month, at least 8 with migraine features. Often develops from episodic migraine. | ~3% of the population |
| Hemiplegic migraine | Temporary paralysis or weakness on one side of the body during aura. Can mimic stroke. | Rare |
| Vestibular migraine | Primary symptom is vertigo/dizziness, with or without headache. | Often underdiagnosed |
| Menstrual migraine | Attacks linked to hormonal fluctuations around menstruation. Estrogen withdrawal is the trigger. | ~60% of female migraineurs |
| Retinal migraine | Temporary vision loss in one eye with or without headache. | Rare |
Root Causes and Triggers
Migraine has a strong genetic component (it runs in families in ~80% of cases), but genetics loads the gun and triggers pull it. Understanding your personal trigger profile is one of the most effective long-term management strategies.
Common Triggers
Hormonal
- Estrogen fluctuations (menstrual cycle, perimenopause)
- Oral contraceptives
- HRT transitions
Dietary
- Aged cheese, alcohol (especially red wine)
- Processed meats (nitrates)
- MSG, artificial sweeteners
- Caffeine withdrawal
- Skipped meals / fasting
Environmental / Lifestyle
- Sleep disruption (too little or too much)
- Stress (and the letdown period after stress)
- Weather/barometric pressure changes
- Strong smells, bright lights, loud noise
- Screen time and blue light
Underlying Contributing Factors
Beyond acute triggers, several systemic factors can increase migraine frequency and severity:
- Gut health: SIBO, intestinal permeability, and histamine intolerance are all associated with increased migraine frequency. The gut-brain axis is a real and measurable pathway.
- Nutrient deficiencies: Magnesium (found deficient in up to 50% of migraineurs), riboflavin (B2), CoQ10, and vitamin D.
- Cervical spine dysfunction: Cervicogenic contributions are often overlooked. Upper cervical misalignment can trigger trigeminal nerve irritation.
- Mast cell activation: MCAS patients have elevated migraine rates. Histamine is a direct trigger for some migraineurs.
- Mitochondrial dysfunction: Evidence suggests migraineurs may have impaired brain energy metabolism, which is why NAD+ therapy and CoQ10 supplementation show benefit.
Regenerative and Integrative Treatment Options
These approaches target the neurobiological mechanisms underlying migraine, not just the symptoms.
Ketamine Infusions
Ketamine is an NMDA receptor antagonist that can break the cycle of central sensitization in chronic migraine. By “resetting” overactive pain-processing circuits, ketamine infusions have shown significant benefit for refractory migraine patients who have failed multiple conventional preventives. Studies report 50-70% reduction in headache days in treatment-resistant patients. Most protocols involve a series of low-dose IV infusions over 3-5 days.
TMS (Transcranial Magnetic Stimulation)
Single-pulse TMS is FDA-cleared for both acute treatment and prevention of migraine with aura. The SpringTMS device can abort attacks during the aura phase by disrupting cortical spreading depression. For prevention, repetitive TMS (rTMS) applied to the motor or prefrontal cortex has shown reduced attack frequency in controlled trials. It is one of the few non-drug, FDA-recognized migraine treatments.
Neurofeedback
Neurofeedback trains the brain to normalize its electrical patterns. Multiple studies show that migraineurs have distinctive EEG signatures (often excessive cortical excitability). Neurofeedback protocols targeting these patterns have shown 50-70% reduction in migraine frequency in several controlled studies, with effects lasting months after treatment ends.
NAD+ IV Therapy
The mitochondrial dysfunction hypothesis of migraine supports the use of NAD+ therapy as a support treatment. NAD+ directly fuels mitochondrial energy production, and the brain is the most energy-demanding organ. While dedicated migraine RCTs are lacking, the mechanistic rationale is strong, and clinical reports of reduced attack frequency after NAD+ protocols are common in integrative neurology practices.
Vagus Nerve Stimulation
The gammaCore device (non-invasive vagus nerve stimulator) is FDA-cleared for both acute and preventive treatment of migraine and cluster headache. It works by stimulating the vagus nerve through the neck, which modulates pain signaling and reduces neuroinflammation. For more on vagus nerve approaches, see our vagus nerve exercises guide.
Evidence-Based Supplements
| Supplement | Dose | Evidence Level | Mechanism |
|---|---|---|---|
| Magnesium (glycinate or oxide) | 400-600 mg/day | Strong (Level A recommendation) | Reduces cortical excitability, NMDA receptor modulation |
| Riboflavin (B2) | 400 mg/day | Strong (Level B) | Mitochondrial energy production |
| CoQ10 | 100-300 mg/day | Moderate (Level C) | Mitochondrial electron transport |
| Feverfew | 50-100 mg/day | Moderate | Anti-inflammatory, parthenolide content |
| Butterbur (Petasites) | 75 mg twice daily | Strong (Level A) but safety concerns | Anti-inflammatory, anti-spasmodic |
The supplement stack most neurologists recommend for migraine prevention
Magnesium 400mg + Riboflavin 400mg + CoQ10 150mg daily. This combination targets the mitochondrial dysfunction hypothesis from three angles, has Level A/B evidence, minimal side effects, and costs under $30/month. Give it 3 months for full effect.
Conventional Treatments (Brief Overview)
Acute (Stopping an Attack)
- Triptans (sumatriptan, rizatriptan): Serotonin receptor agonists. First-line for moderate-severe attacks. Effective but cannot be used more than 9 days/month (medication overuse headache risk).
- CGRP antagonists (ubrogepant/Ubrelvy, rimegepant/Nurtec): Newer, target the CGRP pathway directly. No vasoconstriction risk (safer for cardiovascular patients).
- NSAIDs (ibuprofen, naproxen): First-line for mild-moderate attacks. Best taken early.
- Ditans (lasmiditan/Reyvow): Newer serotonin receptor agonist without cardiovascular risks of triptans. Causes dizziness/drowsiness.
Preventive
- CGRP monoclonal antibodies (erenumab/Aimovig, galcanezumab/Emgality, fremanezumab/Ajovy): Monthly or quarterly injections. Game-changer for many patients. Reduce attacks by 50%+ in responders.
- Beta-blockers (propranolol, metoprolol): Established preventives. Can cause fatigue and low blood pressure.
- Anticonvulsants (topiramate, valproate): Effective but significant side effects (cognitive “fog,” weight changes).
- Botox (onabotulinumtoxin A): FDA-approved for chronic migraine (15+ days/month). 31 injections every 12 weeks. About 50% response rate.
Frequently Asked Questions
When should I see a doctor about migraines?
Seek medical attention if: you have your first severe headache after age 40, your headache pattern changes suddenly, you have neurological symptoms that do not resolve after the headache ends, you are using acute medications more than 2-3 days per week, or your attacks are frequent enough to affect your work and daily life (generally 4+ days per month). Any headache described as “the worst headache of my life” warrants emergency evaluation.
Can migraine be cured?
There is no cure, but the condition can be managed effectively to the point where it minimally impacts your life. Some patients achieve long-term remission with the right combination of prevention, trigger management, and lifestyle optimization. Episodic migraine can also naturally improve with age, particularly after menopause in women.
Are migraines dangerous?
Migraine itself is not dangerous in the vast majority of cases, though it significantly impacts quality of life. There is a small increased risk of ischemic stroke in women who have migraine with aura, particularly those who smoke or use estrogen-containing contraceptives. This is why aura-type migraine and cardiovascular risk factors should be discussed with your doctor.
How do I figure out my triggers?
Keep a detailed headache diary for at least 2-3 months. Track: sleep quality and duration, food and drink intake, weather and barometric pressure, menstrual cycle, stress levels, physical activity, and any environmental exposures. Apps like Migraine Buddy or N1-Headache make this easier. Patterns typically emerge after 8-12 weeks of consistent tracking.
Related Guides
References
- Goadsby PJ, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiological Reviews. 2017;97(2):553-622.
- Ailani J, et al. The American Headache Society consensus statement on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039.
- Peres MFP, et al. Magnesium and migraine: recommendations. Headache. 2016;56(5):931-935.
- Schwartz TH, et al. Ketamine for the treatment of headache: a narrative review. Headache. 2018;58(7):947-959.
- Stokes DA, Lappin MS. Neurofeedback and biofeedback with 37 migraineurs. Behavioral and Brain Functions. 2010;6(9):1-10.
